Ignyta to Present at the Ladenburg Thalmann 2016 Healthcare Conference
September 23 2016 - 4:00PM
Business Wire
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company
focused on precision medicine in oncology, announced today that
Jacob Chacko, M.D., its Chief Financial Officer, will make a
presentation at the Ladenburg Thalmann 2016 Healthcare Conference
on Tuesday, September 27, 2016, at 9:30 a.m. Eastern time (6:30
a.m. Pacific time) in New York, NY, and will discuss Ignyta’s Rx/Dx
approach and review recent updates from ongoing clinical trials of
the company’s robust pipeline of molecularly targeted
therapies.
A webcast of the presentation will be available during the
presentation in the Investors section of the company's website at
http://investor.ignyta.com, and will be archived and available at
that site for 14 days.
About Ignyta, Inc.
At Ignyta, we work tirelessly on behalf of cancer patients
to offer potentially life-saving, precisely targeted therapeutics
(Rx) guided by companion diagnostic (Dx) tests. Our integrated
Rx/Dx strategy allows us to enter uncharted territory, illuminating
the molecular drivers of cancer and quickly advancing treatments to
address them. This approach embraces even those patients with the
rarest cancers, who have the highest unmet need and who may
otherwise not have access to effective treatment options. We are
blazing a new future for cancer patients with our pipeline of
first-in-class and best-in-class precision medicines - with the
ultimate goal of not just shrinking tumors, but eradicating cancer
relapse and recurrence in precisely defined patient
populations.
For more information, please visit: www.ignyta.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160923005828/en/
Ignyta, Inc.Jacob Chacko, M.D.CFO858-255-5959jc@ignyta.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Sep 2023 to Sep 2024